From GlobeNewswire:

SELLAS Life Sciences Group, a biopharmaceutical company focusing on cancer therapies, intends to offer and sell shares of its common stock and warrants to purchase shares in a public offering to fund ongoing operations and clinical development. A.G.P./Alliance Global Partners is the sole placement agent. The offering is subject to market conditions, and will be made pursuant to an effective shelf registration on Form S-3. The Company’s lead product candidate, galinpepimut-S, has the potential to address an array of cancer indications. SELLAS may also develop SLS009, a small molecule used to treat some cancers. Forward-Looking Statements in the press release are subject to significant risks and uncertainties.



Read more: SELLAS Life Sciences Announces Proposed Public Offering